We recently published a list of 12 Best Italian Stocks to Buy in 2025. In this article, we are going to take a look at where Genenta Science S.p.A. (NASDAQ:GNTA) stands against other best Italian stocks to buy in 2025.
As per Deloitte, the broader Italian economy slowed down in 2024, with moderate growth. The service sector expansion was contrasted with continued weakness in essentially all other sectors, mainly in manufacturing and automotive. The consumer and business sentiments in Italy were low across 2024, in the context of weakness in the critical economies of the euro area too.
On the supply side, the broader GDP growth was only supported by the services sector in 2024, while essentially all other sectors witnessed a decline. With these impacts now behind us, what lies ahead for the broader Italian economy?
Inflation Is Expected to Remain Moderate, Says Deloitte
In Italy, inflation slowed down in 2024 and remained the lowest for well-established European economies, added Deloitte. That being said, electricity and gas prices were higher in Italy in comparison to other large European economies including France and Germany, influencing the competitiveness of Italian companies. In 2025, Deloitte sees inflation to remain below the levels expected in the euro area and the ECB target of 2%.
Therefore, moderate inflation, along with nominal wage growth, can result in a gradual recovery in real wages. In general, the broader Italian labor market witnessed a contraction last year. Notably, while the number of employed people continues to increase, hours worked have witnessed a decline, primarily in the industrial sector. Deloitte believes that the broader Italian economy will maintain moderate positive growth in 2025, mainly in line with the anticipated average for euro-area economies. While it can face slightly higher consumer inflation, the levels will be lower than the euro area average. BNP Paribas believes that Italy still has the second lowest inflation in the Eurozone after Ireland. However, as elsewhere, inflation increased in January because of less energy deflation.
READ ALSO: 7 Best Stocks to Buy For Long-Term and 8 Cheap Jim Cramer Stocks to Invest In.
GDP Expansion on the Cards, Says Allianz Trade
As per Allianz Trade, Italy witnessed a strong recovery from the pandemic and was one of the best performers among the 4 major Eurozone economies. Even though GDP is now 5.6% above pre-pandemic levels, the broader economic activity witnessed a slowdown in recent quarters. It even stagnated (in real quarterly terms) in Q3 2024. However, private consumption growth resumed in 2024, with confidence recovering alongside the strong decline of inflation.
Moving forward, Allianz Trade sees private consumption picking up due to a recovery in income and an easing of monetary policy. Notably, a catch-up in NGEU spending is expected to make up for the partial recovery of investment activity. In 2025, the firm anticipates GDP to expand by 0.8%, followed by 1% in the following year.
Our Methodology
To list the 12 Best Italian Stocks to Buy in 2025, we used a screener and sifted through several online rankings. Next, we chose the companies having headquarters in Italy and in which analysts saw upside potential. Finally, the stocks were arranged in ascending order of their average upside potential, as of February 10. We also mentioned hedge fund sentiments from Insider Monkey’s database of 900 elite hedge funds, as of Q3 2024.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Syda Productions/Shutterstock.com
Genenta Science S.p.A. (NASDAQ:GNTA)
Number of Hedge Fund Holders: N/A
Average Upside Potential: ~425.6%
Genenta Science S.p.A. (NASDAQ:GNTA) is a clinical-stage biotechnology company, which is engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Also, it has its headquarters in Milan, Italy. Maxim Group analyst Jason McCarthy maintained a “Buy” rating on the company’s stock, setting a price target of $21.00. The analyst’s rating is backed by a combination of factors related to the promising developments of Genenta Science S.p.A. (NASDAQ:GNTA)’s gene therapy platform, Temferon. The approval of a Phase 1 trial for Temferon in metastatic renal cell cancer (mRCC) by the Agenzia Italiana del Farmaco aligns with European Medicines Agency standards and happens to be a significant milestone.
Temferon is expected to provide a new experimental treatment to patients with late-stage mRCC. Also, the insights gained from Genenta Science S.p.A. (NASDAQ:GNTA)’s uMGMT Glioblastoma Multiforme (TEM-GBM) studies continue to inform and enhance the understanding, demonstrating Temferon’s potential to reprogram the tumor microenvironment and activate the immune system throughout diverse oncology landscapes. In another significant development, the company announced that it has strengthened its partnership with AGC Biologics, which is a global contract development and manufacturing organization (CDMO), by amending the Development and Master Services Agreement.
Notably, this amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta Science S.p.A. (NASDAQ:GNTA)’s cell therapy product, ensuring compliance with cGMP standards. The move improves its production capabilities, potentially enhancing efficiency and reliability in the manufacturing processes.
Overall, GNTA ranks 1st on our list of best Italian stocks to buy in 2025. While we acknowledge the potential of GNTA as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a deeply undervalued AI stock that is more promising than GNTA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
Comments